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Purpose: We evaluated outcomes for pediatric patients who
underwent autologous hematopoietic stem-cell trans-
plantation (AHSCT) for refractory or recurrent Hodgkin
Disease (HD) to identify factors that contribute to the success
or failure of their treatment.
Patients and Methods: From 1988 to 2012, 89 patients <21
years with relapsed or refractory HD underwent high-dose
therapy followed by AHSCT according to one of several
autologous transplantation protocols at Stanford University
Medical Center (Stanford, CA). Pretreatment factors were
analyzed by univariate and multivariate analysis for prog-
nostic signiﬁcance for 5-year overall survival (5 yr OS).
Results: The majority of the patients received a BCNU, eto-
poside, and cyclophosphamide conditioning regimen. The 5
yr OS in these patients was greater than that of recipients of
either other chemotherapy-only preparative (e.g. CCNU, eto-
poside, cyclophosphamide or gemcitabine, vinorelbine, eto-
poside, cyclophosphamide) or radiation-containing regimens
(75%, 61%, 50% respectively; P ¼ .0057). AHSCT at or before
second relapse resulted in better 5 yr OS than AHSCT later in
the disease course (73% v 51%, P ¼ .4). Patients who under-
went AHSCT in 2002 or later had signiﬁcantly better OS than
those who underwent transplantation between 1988 and
2001 (80% v 65%; P¼ .07). Those in the earlier erawere almost
twice as likely to die within 5 years (risk ratio 1.97). This
improvement in outcome is present even among patients
who received BCNU containing conditioning (82% 5 yr OS
2002-2012 vs. 71%5 yrOS1988-2001, P¼ .21, risk ratio 1.89). 5
yrOS correlatedmost stronglywith the eraof transplantation.
Most of the difference in outcome was attributable to
decreased mortality in the peri-transplant period.
Conclusion: Approximatley three-fourths of children who
underwent AHSCT for their recurrent or refractory HD can be
successfully treated with current therapy, conﬁrming the
continued efﬁcacy of this approach. Analyses of results by
treatment era suggest that supportive care during the peri-
transplant period has improved outcomes. The BCNU, eto-
poside, and cyclophosphamide regimen was at least as
effective as BEAM, and had greater OS than many published
reports about outcomes using BEAM. Since outcome was
related to disease status, pediatric patients should undergo
AHSCT prior to second relapse.
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Donor Lymphocyte Infusions in Pediatric Patients with
Malignant and Non-Malignant Diseases After Allogeneic
Bone Marrow Transplantation: A Single Center
Experience
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Donor lymphocyte infusions (DLI) are used after alloge-
neic bone marrow transplantation (allo BMT) to treat and
prevent relapse in patients with leukemia, to prevent graft
rejection for non-malignant diseases, and to treat post-
transplant lymphoprolypherative disorder or viral infections.
The data in children, particularly in non-malignant diseases,
are limited and based on case reports and small series. We
describe our experience in using DLI in pediatric patients
with both malignant and non-malignant diseases after allo
BMT over a 3-year period.
From November 2009 to October 2012, 11 pediatric
patients, median age 9.5 years (range, 1.5-18.5 years), were
treatedwith 22 doses of DLI. Median follow-up duration after
DLI was 7 months (range, 2-32 months).
Six patients had hematological malignancies (3 eacute
lymphoblastic leukemia, 2 e acute myeloid leukemia, 1 e
chronic myeloid leukemia (CML)). DLI was given after salvage
chemotherapy (5 children) to treat relapse and achieve
remission status or to prevent relapse without previous
chemotherapy (1 patient). Median time between BMT and
DLI was 7 months (range, 4-18 months). Median CD3-T-cell
dose of DLI in patients with acute leukemia was 5x107/kg
(range, 1-10); a child with CML received 5 DLIs in escalating
cell doses. Four of six patients had DLI from matched unre-
lated donors, and developed severe multisystemic graft
versus host disease (GVHD).
Five children with non-malignant diseases (2 - thalas-
semia major, 2 - metabolic diseases, 1 - Immunodeﬁciency)
had progressively decreasing chimerism and received DLI to
prevent graft rejection. DLI was given 8 months (median;
range, 2-9 months) after BMT. Median dose was 1x107/kg
(range, 0.1-5). All patients hadmatched family donors (MFD).
In 4/5 children, DLI prevented full rejection. In 2/5 children,
stable mixed chimerism (25-35%) was enough to induce full
remission of their basic disease. All were alive at the end of
follow-up; none had GVHD.
Based on this experience, DLI achieved an excellent
response for the patient with CML; but was not effective for
treatment of full relapse in childrenwith acute leukemia, and
resulted in a high incidence of severe multisystemic GVHD.
DLI could be an effective and safe method to prevent graft
failure in children with non-malignant diseases after MFD.
The absence of GVHD in this group is most likely due to
family donors and reduced cell dose. Prospective studies of
DLI in children are needed.271
Bone Marrow Failure: Congenital Amegakaryocytic
Thrombocytopenia - A Case Report of Successful Matched
Unrelated Bone Marrow Transplantation in Pediatric
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Congenital Amegakaryocytic Thrombocytopenia (CAMT)
is a rare inherited autosomal recessive bone marrow failure
disorder that presents with thrombocytopenia and absence
of megakaryocytes. Bleeding/bruising is typically recognized
on day 1 of life or at least within the ﬁrst month, with risk of
life threatening hemorrhage, requiring platelet transfusions
